Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.

Title

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.

Creator

Keefe Richard S E; Haig George M; Marder Stephen R; Harvey Philip D; Dunayevich Eduardo; Medalia Alice; Davidson Michael; Lombardo Ilise; Bowie Christopher R; Buchanan Robert W; Bugarski-Kirola Dragana; Carpenter William T; Csernansky John T; Dago Pedro L; Durand Dante M; Frese Frederick J; Goff Donald C; Gold James M; Hooker Christine I; Kopelowicz Alex; Loebel Antony; McGurk Susan R; Opler Lewis A; Pinkham Amy E; Stern Robert G

Publisher

Schizophrenia bulletin

Date

2016
2016-01

Description

If treatments for cognitive impairment are to be utilized successfully, clinicians must be able to determine whether they are effective and which patients should receive them. In order to develop consensus on these issues, the International Society for CNS Clinical Trials and Methodology (ISCTM) held a meeting of experts on March 20, 2014, in Washington, DC. Consensus was reached on several important issues. Cognitive impairment and functional disability were viewed as equally important treatment targets. The group supported the notion that sufficient data are not available to exclude patients from available treatments on the basis of age, severity of cognitive impairment, severity of positive symptoms, or the potential to benefit functionally from treatment. The group reached consensus that cognitive remediation is likely to provide substantial benefits in combination with procognitive medications, although a substantial minority believed that medications can be administered without nonpharmacological therapy. There was little consensus on the best methods for assessing cognitive change in clinical practice. Some participants supported the view that performance-based measures are essential for measurement of cognitive change; others pointed to their cost and time requirements as evidence of impracticality. Interview-based measures of cognitive and functional change were viewed as more practical, but lacking validity without informant involvement or frequent contact from clinicians. The lack of consensus on assessment methods was viewed as attributable to differences in experience and education among key stakeholders and significant gaps in available empirical data. Research on the reliability, validity, sensitivity, and practicality of competing methods will facilitate consensus.

Subject

*Schizophrenic Psychology; Antipsychotic Agents/*therapeutic use; Cognition Disorders; Cognition Disorders/diagnosis/psychology/*therapy; cognitive assessment; Functional Assessment; Humans; Interviews; Neuropsychological Tests; neuropsychology; Nootropic Agents/*therapeutic use; Patient Selection; Psychiatric Rehabilitation/*methods; Research Instruments; Schizophrenia; Schizophrenia – Drug Therapy; Schizophrenia/diagnosis/*therapy; Severity of Illness Index; Surveys; treatment; United States Food and Drug Administration

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

19–33

Issue

1

Volume

42

Citation

Keefe Richard S E; Haig George M; Marder Stephen R; Harvey Philip D; Dunayevich Eduardo; Medalia Alice; Davidson Michael; Lombardo Ilise; Bowie Christopher R; Buchanan Robert W; Bugarski-Kirola Dragana; Carpenter William T; Csernansky John T; Dago Pedro L; Durand Dante M; Frese Frederick J; Goff Donald C; Gold James M; Hooker Christine I; Kopelowicz Alex; Loebel Antony; McGurk Susan R; Opler Lewis A; Pinkham Amy E; Stern Robert G, “Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.,” NEOMED Bibliography Database, accessed June 20, 2021, https://neomed.omeka.net/items/show/4209.

Social Bookmarking